spec sheet9 rows
WIN 55,212-2 is a synthetic aminoalkylindole cannabinoid receptor agonist that binds and fully activates both the CB1 and CB2 cannabinoid receptors, and is one of the most widely used reference agonists in endocannabinoid pharmacology. Developed by Sterling Winthrop from the aminoalkylindole (pravadoline) series while researchers were pursuing non-steroidal anti-inflammatory analgesics, it is structurally unrelated to plant-derived cannabinoids like THC yet produces overlapping in vivo effects including antinociception, hypothermia, catalepsy and hypomotility. It is a laboratory tool compound rather than an approved medicine, valued because it is a high-potency full agonist with slight CB2 preference and because its two enantiomers (the active R(+) form versus the near-inactive S(-) WIN 55,212-3) allow clean stereochemical control experiments. It has no approved medical use and is a Schedule I controlled substance in many jurisdictions as a synthetic cannabinoid.
- Full, high-potency agonist at both CB1 and CB2 receptors
- Slight CB2 preference recruits anti-inflammatory signaling
- Potent antinociception in animal pain models
- Neuroprotective; shrinks infarct volume in cerebral ischemia models
- Available as active/inactive enantiomer pair for clean receptor-control experiments
- The field's benchmark reference ligand for endocannabinoid pharmacology
- Sedation, hypomotility and catalepsy in animal models
- Hypothermia (lowered core body temperature)
- Tolerance and dependence with repeated dosing
- Potential dysphoria, anxiety and tachycardia as a full synthetic cannabinoid agonist
Overview
WIN 55,212-2 is hands down the workhorse cannabinoid agonist in the lab; if you have read a receptor paper on the endocannabinoid system, this is pretty much the ligand they benchmarked against. What makes it special is that it is a clean, high-potency full agonist at both CB1 and CB2, and it comes with a near-inactive mirror-image twin (WIN 55,212-3) so you can prove an effect is genuinely receptor-driven and not just some off-target noise.
It is essentially the tool that mapped how CB1 activation quiets neurons, and the ischemia work showing it shrinks infarcts is genuinely striking. Worth being straight though; this is an investigational research chemical, not a supplement or a medicine. It is a potent synthetic cannabinoid, it is scheduled in a lot of places, and it belongs in a pipette, not a stack. It is covered here because understanding it explains basically the whole receptor pharmacology of the field.
Mechanism
WIN 55,212-2 is an aminoalkylindole full at the CB1 and CB2 cannabinoid receptors, both Gi/o-coupled GPCRs. Occupying the orthosteric pocket (it favors an aromatic-stacking mode in transmembrane helix 3, distinct from how THC docks) triggers Gi/o coupling, inhibiting adenylyl cyclase to lower cyclic AMP, opening inwardly-rectifying potassium channels, and closing N- and P/Q-type voltage-gated calcium channels.
Because CB1 sits mostly on presynaptic terminals, that calcium-channel closure suppresses release of and , the retrograde "volume control" behind its antinociceptive, hypothermic and hypomotor effects. Its slight CB2 preference recruits anti-inflammatory signaling on immune and microglial cells. Beyond CB1/CB2 it is a GPR55 and interacts with TRP channels (activating/desensitizing TRPA1, modulating TRPV1); part of its ischemic neuroprotection is mediated indirectly via drug-induced hypothermia.
receptor fingerprint
CB1 receptorFull agonist
CB2 receptorFull agonist
Adenylyl cyclase (via Gi/o)Inhibits
N / P-Q voltage-gated Ca2+ channelsInhibits
GPR55Agonist
TRPA1 channelActivates / desensitizes
TRPV1 channelModulates
Safetyrisks and cautions, not medical advice
WIN 55,212-2 is an investigational research chemical with no approved human medical use and, as a potent synthetic cannabinoid, is a Schedule I controlled substance in many jurisdictions. In animal models it produces the classic cannabinoid "tetrad" (antinociception, hypothermia, catalepsy and suppressed locomotion) along with tolerance and dependence on repeated dosing. As a full agonist it carries the higher risk profile associated with synthetic cannabinoids (tachycardia, sedation, dysphoria/anxiety and, at high exposure, seizures) rather than the milder ceiling of a partial agonist like THC. There is no established safe human dose; it is a laboratory tool, not a therapeutic.
Subjective profileweighing the evidence above
A gold-standard synthetic cannabinoid reference agonist; scientifically indispensable but an investigational, scheduled research chemical, not a supplement.
Resources
This entry is here for reference.
Research
- 1998first citedThe bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insig…
- 1999most active year3 papers
- 2006most recentEstimation of the hypothermic component in neuroprotection provided by cannabinoids following c…
- 1.Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures
- 2.The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes
- 3.The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor
- 4.Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630
- 5.Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia
- 6.In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor
6 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is WIN 55,212-2 used for?
Almost exclusively as a laboratory reference agonist for studying CB1 and CB2 cannabinoid receptors. It has no approved medical use; researchers use it to probe endocannabinoid signaling, pain, inflammation and neuroprotection.
How does WIN 55,212-2 work?
It is a full agonist at the CB1 and CB2 receptors, Gi/o-coupled GPCRs. Activation lowers cyclic AMP, opens potassium channels and closes calcium channels, which suppresses presynaptic release of GABA and glutamate; it also hits GPR55 and TRP channels.
Is WIN 55,212-2 the same as THC?
No. It is a synthetic aminoalkylindole structurally unrelated to plant cannabinoids and binds the receptor differently, yet it produces overlapping in vivo effects. Unlike partial-agonist THC it is a full agonist, so it engages the receptor more completely.
Is WIN 55,212-2 well-researched?
Yes, extensively, but almost entirely in vitro and in animal models. It is one of the most cited cannabinoid tool compounds ever, though there is essentially no clinical human data because it is an investigational research chemical, not a drug candidate.
What are the main risks of WIN 55,212-2?
As a potent full synthetic cannabinoid it carries a higher risk profile than THC; animal work shows hypothermia, catalepsy, tolerance and dependence, and synthetic cannabinoids broadly can cause tachycardia, dysphoria and seizures. It is scheduled in many jurisdictions with no safe established human dose.
Limitations of the evidence
- Investigational research chemical; scheduled and with no established safe human dose
Adverse effects
- Sedation, hypomotility and catalepsy in animal models
- Hypothermia (lowered core body temperature)
- Tolerance and dependence with repeated dosing
- Potential dysphoria, anxiety and tachycardia as a full synthetic cannabinoid agonist